SCHEMBL1074161

SCHEMBL1074161

CC(=CC1C(C(=O)OCc2ccccc2)C1(C)C)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.63
LMNA P02545 3/20 0.60
ADRA2A P08913 1/20 0.60
CNR1 P21554 1/20 0.60
ATM Q13315 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
FABP7 O15540 1/20 0.41
FABP5 Q01469 1/20 0.41
ELANE P08246 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1074157 1.00 TDP1 (0.63) TDP1LMNAADRA2ACNR1ATM
SCHEMBL523193 0.89 TDP1 (0.76) TDP1LMNAADRA2ACNR1ATM
SCHEMBL1073015 0.89 TDP1 (0.51) TDP1LMNAADRA2ACNR1ATM
SCHEMBL1073018 0.89 TDP1 (0.51) TDP1LMNAADRA2ACNR1ATM
SCHEMBL14157372 0.88 TDP1 (0.61) TDP1LMNAADRA2ACNR1ATM
SCHEMBL4991907 0.88 TDP1 (0.84) TDP1LMNAADRA2ACNR1ATM
SCHEMBL1073320 0.88 TDP1 (0.84) TDP1LMNAADRA2ACNR1ATM
SCHEMBL1073323 0.88 TDP1 (0.84) TDP1LMNAADRA2ACNR1ATM
SCHEMBL4433235 0.86 TDP1 (0.76) TDP1LMNAADRA2ACNR1ATM
SCHEMBL22931582 0.86 TDP1 (0.76) TDP1LMNAADRA2ACNR1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1681282-B1 METHOD FOR PRODUCING 3,3-DIMETHYL-2-(1-PROPENYL) CYCLOPROPANE CARBOXYLATE SUMITOMO CHEMICAL CO (JP) 2013-01-23 EP disclosed
EP-1797953-B1 PROCESS FOR PRODUCING OXYGENIC COMPOUND SUMITOMO CHEMICAL CO (JP) 2011-01-05 EP disclosed
US-7393971-B2 Method for producing 3,3-dimethyl-2-(1-propenyl) cyclopropanecarboxylate SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-07-01 US disclosed
US-20080064898-A1 Method for Producing Oxygen-Containing Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-13 US disclosed
US-7276622-B2 Method for producing oxygen-containing compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-10-02 US disclosed
EP-1797953-A1 PROCESS FOR PRODUCING OXYGENIC COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-06-20 EP disclosed
US-20070078278-A1 Method for producing 3, 3-dimethyl-2-(1-propenyl) cyclopropanecarboxylate SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2007-04-05 US disclosed
US-20060173221-A1 Method for producing oxygen-containing compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-08-03 US disclosed
EP-1681282-A1 METHOD FOR PRODUCING 3,3-DIMETHYL-2-(1-PROPENYL) CYCLOPROPANE CARBOXYLATE Sumitomo Chemical Company, Limited (JP) 2006-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064898-A1 Method for Producing Oxygen-Containing Compound AOC2, AOX1, CAT TDP1 4391/4885LMNA 3622/4885ADRA2A 3643/4885
US-20070078278-A1 Method for producing 3, 3-dimethyl-2-(1-propenyl) cyclopropanecarboxylate AOC3, PDXK, AIPL1 TDP1 3871/4885LMNA 2611/4885ADRA2A 2097/4885
US-20060173221-A1 Method for producing oxygen-containing compound GPX4, DUOX2, SCO2 TDP1 4530/4885LMNA 4036/4885ADRA2A 4831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.